Neoantigen-based Personalized Cancer Therapeutic Vaccines Treatment, Companies, Market Trends | Neoantigen-based Personalized Cancer Therapeutic Vaccines Infographic

Cancer therapeutic Vaccines utilize the weakened or killed viruses, bacteria, or other germs to start an immune response in the body. These vaccines are designed to work similarly, helping the immune system to recognize, attack and destroy cancer cells.

Neoantigen-based Personalized Cancer therapeutic Vaccines lets the immune system to recognize cancer cells as foreign, and hence, get the immune system to kill the cancer cells.

Cancer neoantigens derived from random somatic mutations in tumour tissue represent a promising approach of targets for the cancer immunotherapies, including cancer vaccine. Vaccination against the tumour-specific neoantigens minimizes the potential induction of central and peripheral tolerance as well as the risk of autoimmunity. Neoantigen-based cancer vaccines have recently showed marked therapeutic potential in both preclinical and early-phase as well as late-phase clinical studies.

Neoantigens are highly immunogenic as they are not expressed in normal tissues. They can activate CD4+ and CD8+ T cells to generate an immune response and have the potential to become new targets of tumour immunotherapy. The development of bioinformatics technology has accelerated the identification of neoantigens.

Tumour vaccines targeting neoantigens mainly include nucleic acid, dendritic cell (DC)-based, tumour cell, and long synthetic peptide (SLP) vaccines.

Neoantigen-based cancer vaccines also target several other indications like:-